4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) *FluoroPure grade* from Molecular Probes (Invitrogen)
Essential Data: Gel Electrophoresis from Promega
Human MMP-7 (Total) ELISpot Kit from R&D Systems
...Kit, 1. Select from homogeneous and gradient polya...enaturing, native, and isoelectric focusing gels.S...gels, buffer strips, and staining kits.Achieve det...opes with ready-to-use silver staining kits. Categ...
Biology Products:(Date:11/24/2009)... , SEATTLE, Nov. 24 Blue Mar...and the Odessa Public Development Authority (OPDA)...ate,s Community Economic Revitalization Board (CER...e state,s first specialty biochemical biorefinery ...ll significantly speed the development of our bior...
(Date:11/24/2009)... , , Primary efficacy endpoint has been ...ent endometrial cancer, , QUEBEC CITY, Nov. 2...NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a globa...herapy and oncology, today announced positive effi...ytotoxic peptide conjugate, AEZS-108 (formerly AN-...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-Firs...he global specialty biopharmaceutical company, tod...ropean Medicines Agency for,velaglucerase alfa, th...ent,for the treatment of Type 1 Gaucher disease. T...cerase alfa that has been submitted, with previous...
(Date:11/24/2009)... , REDWOOD CITY, Calif., Nov. 24 /PRNewswi...DX ) today announced that Randy Scott, Genomic Hea... Annual Piper Jaffray Health Care Conference in Ne...a.m. ET. ,, To access the live and subsequentl...Investor Relations section of Genomic Health,s web...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2